Intravenous Administration of Stable‐Labeled N‐Acetylcysteine Demonstrates an Indirect Mechanism for Boosting Glutathione and Improving Redox Status

Publisher： John Wiley & Sons Inc

E-ISSN： 1520-6017|104|8|2619-2626

ISSN： 0022-3549

Source： JOURNAL OF PHARMACEUTICAL SCIENCES (ELECTRONIC), Vol.104, Iss.8, 2015-08, pp. : 2619-2626

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

There is an increasing interest in using N‐acetylcysteine (NAC) as a treatment for neurodegenerative disorders to increase glutathione (GSH) levels and its redox status. The purpose of this study was to characterize the biosynthesis of NAC to GSH using a novel stable isotope‐labeled technique, and investigate the pharmacodynamics of NACin vivo. Female wild‐type mice were given a single intravenous bolus dose of 150 mg kg−1 stable‐labeled NAC. Plasma, red blood cells (RBC), and brain tissues were collected at predesignated time points. Stable‐labeled NAC and its metabolite GSH (both labeled and unlabeled forms) were quantified in blood and brain samples. Molar ratios of the reduced and oxidized forms of GSH (GSH divided by glutathione disulfide, redox ratio) were also determined. The elimination phase half‐life of NAC was approximately 34 min. Both labeled and unlabeled GSH in RBC were found to increase; however, the area under the curve above baseline (AUCb0–280) of labeled GSH was only 1% of the unlabeled form. These data indicate that NAC is not a direct precursor of GSH. In addition, NAC has prolonged effects in brain even when the drug has been eliminated from systemic circulation. © 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:2619–2626, 2015